Enabling better genetic medicines with enzymatic DNA

Nature's Building Blocks

In this short film. Dr Helen Horton, CRO and Dr Tommy Duncan, COO explain the rise of genetic medicine and the existing industry challenges associated with DNA. The traditional industry approach uses plasmid DNA in production. This approach is incredibly time-consuming, costly and involves the difficulty of growing genetically engineered bacteria in vast fermentation tanks to harvest DNA, creating a bottleneck for DNA in industry. Additionally, plasmid DNA contains unwanted DNA sequences such as the presence of antibiotic resistant genes in the final product which is an increasing area of concern. 

Introducing Touchlight’s enzymatic doggybone DNA as an alternative to plasmid. The novel DNA vector and enzymatic manufacturing process, uses enzymes to amplify specific sequences of genetic code. Enzymes are incredibly precise and extremely efficient allowing Touchlight to manufacture DNA faster, with high purity, containing only the desired gene.

Genetic medicine is at an exciting point in its evolution, and doggybone DNA can play a key role in its rapid development.